Well it was extremely pleasant to see the share price coming home after work. But after seeing the why, I does seem a somewhat hollow victory.
Clearly the results to be released in early Q2 with Keytruda were obviously very good and Merck made their move prior to any announcements.
We better see those results before the shareholder vote so we have the opportunity to reject the offer.